This study is looking at the safety and early effects of a treatment called Q-Cells for people with Transverse Myelitis. Q-Cells are made of human cells that are thought to help repair damage in the spinal cord by replacing damaged cells and supporting nerve fibers. The study aims to see if Q-Cells are safe and well-tolerated when transplanted into the spinal cord. It plans to enroll up to 9 participants between 18 and 70 years old. The main goal is to track any side effects for 9 months after the treatment. The current status of the study is unclear.

Study design

This is an open-label study, meaning you and the study team will know you are receiving the treatment, but you will be blinded to which side of your spinal cord receives the treatment. It plans to enroll up to 9 participants.

What's involved

Your participation will involve a screening period, a treatment period where Q-Cells are transplanted, and a post-treatment follow-up, lasting generally 9 to 12 months in total.

Compensation

Not stated in the trial record.

Follow-up

You will be followed for 9 months after the Q-Cells transplantation. If you agree, you can continue to be followed for safety and activity in a separate long-term study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.